Premium
Real‐world treatment patterns and clinical outcomes of HCV treatment‐naive patients in China: an interim analysis from the CCgenos study
Author(s) -
Rao Huiying,
Li Hong,
Chen Hong,
Shang Jia,
Xie Qing,
Gao ZhiLiang,
Li Jun,
Sun Yongtao,
Jiang Jianning,
Wang Lei,
Zhao Longfeng,
Zhang Lunli,
Yang Weibo,
Niu Junqi,
Gong Zuojiong,
Gong Guozhong,
Yang Ruifeng,
Lee MeiHsuan,
Wei Lai
Publication year - 2017
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.13467
Subject(s) - medicine , interim analysis , cirrhosis , hepatitis c virus , hepatitis c , cohort , interferon , gastroenterology , clinical trial , immunology , virus
Background and Aim In China, chronic hepatitis C virus (HCV) infection represents a considerable healthcare burden. Although interferon‐based therapy has been the standard‐of‐care for many years, few long‐term, real‐life studies have assessed interferon‐based treatment in China. The objective of CCgenos follow‐up study was to analyze long‐term treatment patterns and outcomes in a cohort of treatment‐naïve, Han ethnic, patients with chronic HCV infection. Methods Patients who had participated in the CCgenos cross‐sectional study were invited to enter this 5‐year follow up. Clinical information and centralized HCV‐RNA measures were collected at scheduled study visits every 6 months for untreated patients and every 3 months for treated patients. Results Among 512 patients enrolled, 334 (65.2%) received interferon‐based treatment and 178 (34.8%) remained untreated over a median of 4.1 (1.2–4.3) years. A total of 82.8% (424/512) of patients had an IL28B CC genotype (GT); 60.7% (311/512) had HCV GT1b infection, including 121 (38.9%) untreated. Most patients with baseline cirrhosis were untreated (26/46, 56.5%). Among patients who completed treatment and 24 weeks of post‐treatment follow up, the duration of interferon‐based therapy was frequently longer than recommended (52.9% [92/174] of GT1b‐infected were treated for > 1 year). Rates of sustained virologic response (SVR24) were 71.1% (226/318) overall; 62.4% (111/178) among patients with HCV GT1b infection; and 42.9% (15/35) among patients with cirrhosis. Conclusions There remains a high unmet need for effective HCV treatment in China, evidenced by a high proportion of patients remaining untreated by the current standard‐of‐care and relatively low SVR24 rates for patients with both GT1b infection and cirrhosis.